Chronic lead treatment accelerates photochemically induced platelet aggregation in cerebral microvessels of mice, in vivo.
Effects of two chronic treatment levels with lead on platelet aggregation in cerebral (pial) microcirculation of the mouse were investigated. Exposure to lead was made by subcutaneous injections for 7 days of lead acetate dissolved in 5% glucose solution, vehicle. Two doses of lead were used, a low dose of 0.1 mg/kg and a high dose of 1.0 mg/kg. Adult male mice were divided into three groups, 10 each; one group was injected with vehicle (control), another was injected with the low dose, and the third was injected with the high dose. Additional mice were used for the determination of hematological parameters and for the lead level in serum of the three groups. On the eighth day, platelet aggregation in pial microvessels of these groups of mice was carried out in vivo. Animals were anesthetized (urethane, 1-2 mg/g, ip), the trachea was intubated, and a craniotomy was performed. Platelet aggregation in pial microvessels was induced photochemically, by activation of circulating sodium fluorescein (0.1 mg/25 g, iv) with an intense mercury light. The time required for the first platelet aggregate to appear in pial arterioles was significantly shorter in the lead-treated mice than in control. This effect was in a dose-dependent manner; 113 +/- 44 sec for low dose and 71 +/- 18 sec for high dose vs 155 +/- 25 sec for control, P < 0.02 and P < 0.001, respectively. Between the two lead-treated groups, the high dose significantly (P < 0.05) shortened the time to first aggregate. These data evidenced an increased susceptibility to cerebrovascular thrombosis as a result of exposure to lead.
al Dhaheri
A H
AH
Department of Hematology, Al Ain Hospital, United Arab Emirates.
el-Sabban
F
F
Fahim
M A
MA
D000818:Animals; D001921:Brain / Q000098:blood supply / Q000187:drug effects*; D004781:Environmental Exposure / Q000009:adverse effects*; D019793:Fluorescein; D005452:Fluoresceins / Q000494:pharmacology; D007854:Lead / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D008297:Male; D051379:Mice; D008833:Microcirculation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*
D005452:Fluoresceins; D007854:Lead; D019793:Fluorescein